Patient Reported Outcomes in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata

被引：0
|
作者：
Mesinkovska, Natasha Atanaskova [1 ]
Senna, Maryanne Makredes [2 ]
Mostaghimi, Arash [3 ]
King, Brett [4 ]
Hamilton, Colleen [5 ]
Cassella, James [6 ]
机构：
[1] Univ Calif Irvine, Clin Res, Irvine, CA USA
[2] Lahey Hosp & Med Ctr, Hair Loss Ctr Excellence, Burlington, MA USA
[3] Brigham & Womens Hosp, Dept Dermatol, Boston, MA USA
[4] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT USA
[5] Concert Pharmaceut, Clin Operat, Lexington, MA USA
[6] Concert Pharmaceut, Lexington, MA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：AB204 / AB204
页数：1
相关论文
共 41 条
  • [31] Early changes in patient-relevant endpoints in three tralokinumab pivotal phase III trials (ECZTRA 1-3) in adult patients with moderate-to-severe atopic dermatitis
    Silverberg, J. I.
    Cork, M.
    Wollenberg, A.
    Katoh, N.
    Steffensen, L. A.
    Kurbasic, A.
    Olsen, C. K.
    Kuznetsova, A.
    Osterdal, M. L.
    Vilsboll, A. W.
    Deleuran, M.
    Simpson, E.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E64 - E64
  • [32] OLOKIZUMAB IMPROVES PATIENT REPORTED OUTCOMES IN MODERATE TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS PATIENTS INADEQUATELY CONTROLLED BY METHOTREXATE (MTX-IR): RESULTS FROM THE PHASE 3 RANDOMIZED CONTROLLED TRIAL, CREDO 2
    Strand, V.
    Choy, E.
    Nasonov, E.
    Lisitsyna, T.
    Lila, A.
    Kuzkina, S.
    Samsonov, M.
    Feist, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 43 - 44
  • [33] Improvement in patient-reported hair loss outcome measures in patients with alopecia areata treated with ritlecitinib: 48-week results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial
    Sinclair, Rodney
    Mesinkovska, Natasha
    Mitra, Debanjali
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB69 - AB69
  • [34] Improvement In Respiratory Symptoms In Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease Patients Treated With Sun-101 (glycopyrrolate/eflow®) - Patient-Reported Outcomes From The Phase 3 Golden Studies
    Donohue, J. F.
    Ferguson, G. T.
    Kerwin, E. M.
    Ozol-Godfrey, A.
    Ganapathy, V.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [35] Impact of baricitinib on patient-reported skin symptoms, itch, and quality of life in adult patients with moderate to severe atopic dermatitis and an inadequate response to topical therapies from phase 3 trials BREEZE-AD1 and BREEZE-AD2
    Lio, Peter
    Nosbaum, Audrey
    Cardillo, Tracy
    DeLozier, Amy
    Gamalo, Margaret
    Ball, Susan G.
    Bieber, Thomas
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB28 - AB28
  • [36] Clinically meaningful improvements in patient-reported outcomes and itch: analysis of a phase II clinical trial in adults with moderate-to-severe atopic dermatitis treated with etrasimod, a novel, oral selective sphingosine 1-phosphate receptor modulator
    Murrell, D. F.
    Guttman-Yassky, E.
    Bissonnette, R.
    Kircik, L.
    Selfridge, A.
    Liu, K.
    Ahluwalia, G.
    Silverberg, J. I.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E140 - E141
  • [37] Dupilumab improves patient-reported global assessments of disease severity and treatment effect: Data from a 16-week phase 3 placebo-controlled trial in adolescent patients with moderate to severe AD (LIBERTY AD ADOL)
    Simpson, Eric L.
    Guttman, Emma
    Bansal, Ashish
    Chen, Zhen
    Rossi, Ana Beatris
    Gadkari, Abhijit
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB33 - AB33
  • [38] Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial
    Richardson, Paul G.
    Schlossman, Robert L.
    Roy, Anuja N.
    Panneerselvam, Ashok
    Acharyya, Suddhasatta
    Sopala, Monika
    Lonial, Sagar
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (05) : 628 - 636
  • [39] Patient reported outcomes (PROs) of multiple myeloma (MM) patients treated with panobinostat (PAN) after?2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled, PANORAMA-1 trial.
    Richardson, Paul G.
    Lonial, Sagar
    Schlossman, Robert L.
    Roy, Anuja Nidumolu
    Majer, Istvan
    Panneerselvam, Ashok
    Sopala, Monika
    Miguel, Jesus San
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3TULIP-1 and TULIP-2 trials of anifrolumab
    Strand, Vibeke
    O'Quinn, Sean
    Furie, Richard A.
    Morand, Eric F.
    Kalunian, Kenneth C.
    Schwetje, Erik G.
    Abreu, Gabriel
    Tummala, Raj
    LANCET RHEUMATOLOGY, 2022, 4 (03): : E198 - E207
12345